Horizon’s Krystexxa with methotrexate meets primary endpoint in trial
The trial is designed to assess the use of Krystexxa with methotrexate to help patients achieve durable response to therapy.
Ireland
Latest in
Ireland
ICON closes $12bn acquisition of PRA Health Sciences
The merged company will operate as ICON from 150 locations across 47 countries.
Horizon Therapeutics enrols first subject in uncontrolled gout trial
Horizon Therapeutics has enrolled the first patient in a clinical trial of Krystexxa (pegloticase injection) plus methotrexate for treating people…
Ireland’s ICON signs agreement to acquire PRA Health Sciences
Irish company ICON has agreed to acquire contract research company PRA Health Sciences in a cash and stock deal valued…
Irish researchers test alpha-1-antitrypsin for Covid-19
Researchers at RCSI University of Medicine and Health Sciences in Ireland have started a clinical trial to assess alpha-1-antitrypsin as…
Accenture and Bayer to implement INTIENT Clinical platform
Accenture will partner with Bayer to implement the Accenture INTIENT Clinical platform for research, clinical development, pharmacovigilance and patient services.
PCI Pharma to invest in new clinical facility in Dublin
PCI Pharma is set to invest in a new clinical facility near Dublin, Ireland to significantly increase capabilities and capacity…
Alkermes reports positive results for Aristada in schizophrenia
Irish biopharmaceutical company Alkermes has reported positive top-line data from the Phase IIIb ALPINE clinical trial of Aristada (aripiprazole lauroxil)…